Deep Dive STE Joint Venture Top Monthly Gainer Debt Free
NYQ Β· Healthcare Β· Medical Devices
$210.28
-3.38 (-1.58%)
STE Interactive Price Chart & Trading Signals
STE Stock Snapshot β Valuation, Risk & Technical Signals
STE Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$20.50B
P/E Ratio
25.71
Forward P/E
17.17
PEG Ratio
1.78
P/B Ratio
2.84
EPS
$8.18
Dividend Yield
1.21%
52W Range
$195.14 β $269.44
Beta
0.91
Volume
0.8M
ROE
11.4%
Profit Margin
13.3%
Revenue Growth
7.3%
Gross Margin
44.4%
EV/EBITDA
13.46
Analyst Target
$263.13
The trailing price-to-earnings ratio stands at 25.7x. Forward P/E of 17.2x implies earnings expansion expected. Price-to-book is 2.84x. EV/EBITDA sits at 13.46x. Market capitalization is $20.50B. Revenue is growing at 7.3% on a trailing basis. Earnings are expanding at 14.0%. Profit margins are 13.3%. Return on equity is 11.4%. Beta of 0.91 indicates market-average volatility.
Analyst Consensus
Recommendation
Buy
Low Target
$232.00
Mean Target
$263.13
High Target
$280.00
Based on 8 analysts
About STE
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
STE Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuationData confidence
HighSTERIS plc (STE) trades above our multi-model fair value estimate of $163.92 by approximately 22.0%. Trailing P/E: 25.7x. Profitability signals include profit margin of 13.3% and return on equity of 11.4%. Recent growth metrics show revenue growth of 7.3% and earnings growth of 14.0%. Risk profile: beta of 0.91. Consensus: buy.
STE Deep Dive Analysis
Valuation
Overvalued
P/E 25.7x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 7.3%
Revenue is outpacing the market.
Valuation Snapshot
STERIS plc (STE) trades above our multi-model fair value estimate of $163.92 by approximately 22.0%. The trailing price-to-earnings ratio stands at 25.7x. Forward P/E of 17.2x suggests earnings compression ahead. Price-to-sales is 3.4x. Price-to-book is 2.8x. EV/EBITDA sits at 13.5x. Market capitalization is $20.50B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 7.3% on a trailing basis. Earnings are expanding at 14.0%. Profit margins are 13.3%. Return on equity is 11.4%. Return on assets is 6.8%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.91 indicates market-average volatility. Net debt position is $1.56B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $263.13 implies 25.1% upside. Target range spans $232.00 to $280.00. 8 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, market cap: Yahoo Finance (delayed ~5 min)
- P/E, EPS, revenue, debt: Yahoo Finance fundamentals
- Analyst targets: Yahoo Finance consensus (may lag)
- Insider trades: SEC EDGAR Form 4 filings
QuantSoar Model (Derived)
- Fair Value: 7-model consensus (DCF, Graham, P/E, P/S, DDM, EV/EBITDA, Div Yield) β trimmed inverse-variance weighted
- Margin of Safety = (Fair Value β Live Price) / Live Price Γ 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation(Β±25) + Whale(Β±10) + Macro(Β±10) + Technical(Β±10). Analyst consensus shown separately.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
STE Overvalued
STERIS plc (STE) trades above our multi-model fair value estimate of $163.92 by approximately 22.0%.
Frequently Asked Questions
ValuationIs STE stock overvalued right now?
ValuationWhat is STE fair value based on current fundamentals?
RiskHow risky is STE compared with other stocks?
GrowthIs STE still growing?
AnalystWhat do analysts think about STE?
DividendDoes STE pay a dividend?
CatalystWhat could change the investment case for STE?
Related Stocks
About the Author
Phasakorn Traklang (Peach) β Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.